Jack Allen
Stock Analyst at Baird
(0.94)
# 2,675
Out of 4,416 analysts
31
Total ratings
35%
Success rate
-22.25%
Average return
Main Sectors:
Top Industries:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Maintains: Outperform | $63 → $77 | $52.69 | +46.14% | 4 | Feb 29, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $54 | $11.30 | +377.88% | 6 | Jan 19, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $10 → $7 | $0.90 | +677.95% | 2 | Dec 12, 2023 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $60.23 | +39.47% | 1 | Oct 31, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $6 → $8 | $2.57 | +211.28% | 4 | Aug 15, 2023 | |
| CARM Carisma Therapeutics | Reiterates: Outperform | $10 | $1.62 | +517.28% | 2 | Jun 28, 2023 | |
| VOR Vor Biopharma | Maintains: Outperform | $38 → $22 | $1.80 | +1,122.22% | 2 | Mar 24, 2023 | |
| CRSP CRISPR Therapeutics AG | Initiates: Neutral | $46 | $55.89 | -17.70% | 1 | Mar 7, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $58 → $42 | $23.60 | +77.97% | 1 | Feb 24, 2023 | |
| ALLO Allogene Therapeutics | Upgrades: Outperform | $12 | $2.97 | +304.04% | 2 | Jan 6, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $5 | $1.06 | +371.70% | 1 | Nov 2, 2022 | |
| FATE Fate Therapeutics | Initiates: Neutral | $28 | $4.06 | +589.66% | 1 | Jun 3, 2022 | |
| CLLS Cellectis | Upgrades: Outperform | n/a | $2.99 | - | 2 | May 18, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.98 | - | 1 | Nov 9, 2021 | |
| VYGR Voyager Therapeutics | Upgrades: Outperform | n/a | $8.81 | - | 1 | Oct 7, 2021 |
Arcellx
Feb 29, 2024
Maintains: Outperform
Price Target: $63 → $77
Current: $52.69
Upside: +46.14%
Instil Bio
Jan 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $11.30
Upside: +377.88%
bluebird bio
Dec 12, 2023
Maintains: Outperform
Price Target: $10 → $7
Current: $0.90
Upside: +677.95%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $60.23
Upside: +39.47%
Taysha Gene Therapies
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.57
Upside: +211.28%
Carisma Therapeutics
Jun 28, 2023
Reiterates: Outperform
Price Target: $10
Current: $1.62
Upside: +517.28%
Vor Biopharma
Mar 24, 2023
Maintains: Outperform
Price Target: $38 → $22
Current: $1.80
Upside: +1,122.22%
CRISPR Therapeutics AG
Mar 7, 2023
Initiates: Neutral
Price Target: $46
Current: $55.89
Upside: -17.70%
Intellia Therapeutics
Feb 24, 2023
Maintains: Neutral
Price Target: $58 → $42
Current: $23.60
Upside: +77.97%
Allogene Therapeutics
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $2.97
Upside: +304.04%
Lineage Cell Therapeutics
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.06
Upside: +371.70%
Fate Therapeutics
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $4.06
Upside: +589.66%
Cellectis
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.99
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.98
Upside: -
Voyager Therapeutics
Oct 7, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.81
Upside: -